FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549	
-------------	------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hasija Amit</u>					2. Issuer Name and Ticker or Trading Symbol Milestone Pharmaceuticals Inc. [MIST]							(Che	elationship o ck all applica Director	able)	g Perso	10% Ov	ner	
(Last) (First) (Middle) C/O MILESTONE PHARMACEUTICALS INC.					3. Date of Earliest Transaction (Month/Day/Year) 03/24/2021						>	X Officer (give title below) Other (specify below) CFO & EVP of Corp. Development						
1111 DR. FREDERIK-PHILIPS BLVD, STE 420				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. In	6. Individual or Joint/Group Filing (Check Applicable					
(Street) MONTR	EAL A	8	H4M 2X6		,,,						Line)							
(City)	(S	tate)	(Zip)										1 613011					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			te	Execution Date		Code (Instr.				5. Amoun Securities Beneficia Owned Fo	s For ally (D) ollowing (I)		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V Amount (A) or (D)					Price	Transaction(s) (Instr. 3 and 4)							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	nsaction Derivative E			Expiration Date (Month/Day/Year) Underlying Derivative Secu			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		oiration te	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Employee Stock Option (right to buy)	\$6.26	03/24/2021		A		240,000		(1)	03/2	24/2031	Common Shares	240,000	\$0.00	240,00	00	D		

Explanation of Responses:

1. One-fourth (1/4th) of the shares subject to the option vest on March 24, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

/s/ Eric Popp, Attorney-in-Fact 03/26/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.